Previous studies by the Smyth group reported potent tumor inhibition by administering an anti-CD1d blocking antibody in mice bearing multiple types of CD1d-deficient tumors, presumably by blocking the suppressive functions of type II NKT cells [37], [53], [54]. Here, CD1D is linked to neoplasm.